Publication:


abstract

BACKGROUND AND OBJECTIVES:

Despite reporting estimated GFR (eGFR), use of evidence-based interventions in CKD remains suboptimal. This study sought to determine the effect of an enhanced eGFR laboratory prompt containing specific management recommendations, compared with standard eGFR reporting in CKD.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:

A cluster randomized trial of a standard or enhanced eGFR laboratory prompt was performed in 93 primary care practices in Alberta, Canada. Although all adult patients with CKD (eGFR <60 ml/min per 1.73 m(2)) were included, medication data were only available for elderly patients (aged ≥66 years). The primary outcome, the proportion of patients with diabetes or proteinuria receiving an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), was assessed in elderly CKD patients.

RESULTS:

There were 5444 elderly CKD patients with diabetes or proteinuria who were eligible for primary outcome assessment, irrespective of baseline ACEi/ARB use. ACEi/ARB use in the subsequent year was 77.1% and 76.9% in the standard and enhanced prompt groups, respectively. In the subgroup of elderly patients with an eGFR <30 ml/min per 1.73 m(2), ACEi/ARB use was higher in the enhanced prompt group. Among 22,092 CKD patients, there was no difference in the likelihood of a composite clinical outcome (death, ESRD, doubling of serum creatinine, or hospitalization for myocardial infarction, heart failure, or stroke) over a median of 2.1 years.

CONCLUSIONS:

In elderly patients with CKD and an indication for ACEi/ARB, an enhanced laboratory prompt did not increase use of these medications.

Related Articles
Review Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Cochrane Database Syst Rev. 2011
Review Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C. Cochrane Database Syst Rev. 2011 Oct 5; (10):CD007751. Epub 2011 Oct 5.
Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.
Heart Vessels. 2010
Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.
Omae K, Ogawa T, Nitta K. Heart Vessels. 2010 May; 25(3):203-8. Epub 2010 May 29.
Associations of kidney function with cardiovascular medication use after myocardial infarction.
Clin J Am Soc Nephrol. 2008
Associations of kidney function with cardiovascular medication use after myocardial infarction.
Winkelmayer WC, Levin R, Setoguchi S. Clin J Am Soc Nephrol. 2008 Sep; 3(5):1415-22. Epub 2008 Jul 9.
Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment
2012
Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment
Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ. 2012 Jan
Review Aldosterone antagonists for preventing the progression of chronic kidney disease.
Cochrane Database Syst Rev. 2009
Review Aldosterone antagonists for preventing the progression of chronic kidney disease.
Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Cochrane Database Syst Rev. 2009 Jul 8; (3):CD007004. Epub 2009 Jul 8.